Daiichi Sankyo Co. Ltd., of Tokyo, reported top-line results from its phase III NEUCOURSE trial testing mirogabalin in 765 Asian patients with postherpetic neuralgia. The trial met its primary endpoint with mirogabalin reducing the weekly average daily pain score from baseline to week 14 compared to placebo. Daiichi plans to present full results from NEUCOURSE and a second phase III trial, ALDAY, at an upcoming scientific conference. Read More
TAIPEI, Taiwan – Artificial intelligence is already changing health care, but the revolution is only just beginning, and within the coming decade it will have completely transformed the biotech industry as we know it. Read More
TAIPEI, Taiwan – Taiwan's biopharma industry faces strong competition from both China and South Korea, but its geographic position on the edge of Southeast Asia provides an advantage in marketing a potential dengue vaccine to the young and fast-growing region. Read More
HONG KONG – Scientists at the Riken Brain Science Institute (BSI) have linked low levels of the neurotransmitter serotonin to the symptoms of autism spectrum disorder (ASD) in young mice, suggesting selective serotonin reuptake inhibitors (SSRIs) may have a role in treating autism in humans. Read More
TAIPEI, Taiwan – One of the more interesting questions in biopharma today is the direction in which the biosimilars market is headed. Speaking at the recent BioBusiness Asia Conference, part of BioTaiwan 2017, industry insiders shared their views on the outlook for this market, highlighting the state of flux and uncertainty that still defines the segment. Read More
CEO Sofie Qiao told BioWorld Asia that Vivace Therapeutics Inc. can "probably get into the clinic in the next couple of years" with its lead program – an inhibitor that operates in the Hippo-YAP signaling pathway – thanks to $25 million raised in a series B round. The money supplements $15 million garnered by way of the series A financing in 2015, when the San Mateo, Calif.-based firm was founded. Read More
HONG KONG – Sinovac Biotech Ltd., China's leading vaccine maker, is in the midst of a go-private transaction that has morphed into a heated bidding war. Read More
